Vasoconstrictor drugs may improve renal function in hepatorenal syndrome (HRS), but the
effect on mortality has not been established. We therefore performed a systematic review of …

Background Hepatorenal syndrome (HRS) is a severe and progressive functional renal
failure occurring in patients with cirrhosis and ascites. Terlipressin is recognized as an …

Introduction: Hepatorenal syndrome (HRS) is a unique form of acute kidney injury seen in
cirrhotic patients and associated with significant mortality and morbidity. Despite its impact …

Background Hepatorenal syndrome (HRS) is a severe complication of end-stage renal
disease whose management still constitutes a big challenge. Various approaches have …

Background Hepatorenal syndrome type 1 (HRS 1) is a functional, rapidly progressive,
potentially reversible form of acute kidney injury occurring in patients with cirrhosis …

Background The hepatorenal syndrome is a severe and well‐known complication of end‐
stage liver disease, but its management is controversial. Recent reports have shown the …

BACKGROUND & AIMS: Hepatorenal syndrome (HRS) type 1 is a progressive functional
renal failure in subjects with advanced liver disease. The aim of this study was to evaluate …

Background Hepatorenal syndrome (HRS) is a common complication in patients with
cirrhosis or fulminant liver failure. We systematically reviewed the benefits and harms of …

Background The vasoconstrictor terlipressin is used for type 1 hepatorenal syndrome (HRS-
1) in many parts of the world and is part of the clinical practice guidelines in Europe …

BACKGROUND & AIMS: Various vasoconstrictors are useful in the management of
hepatorenal syndrome (HRS). Terlipressin is the drug of choice; however, it is expensive. In …